TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In a randomized controlled trial led by the University of Surrey, 61 participants took NOVOS Core or a placebo daily for six months. The supplement group had more favorable results for endothelial function, arterial stiffness and systolic blood pressure, but the trial did not establish whether these changes prevent heart attacks, strokes or other cardiovascular events.
A randomized controlled trial led by the University of Surrey found that participants taking the multi-ingredient supplement NOVOS Core for six months had improved results on three measures of vascular health compared with a placebo group. The study measured endothelial function, arterial stiffness and systolic blood pressure, but was not designed to determine whether the changes reduce cardiovascular events or improve long-term health.
The trial included 61 participants: 33 received NOVOS Core and 28 received a placebo, taken once daily for six months. Researchers also observed a change in blood vessel function within an hour of the first dose. The report does not establish how long that immediate response lasted.
Flow-mediated dilation, a measure of how well blood vessels respond to changes in blood flow, improved in the supplement group relative to the control group. At six months, the adjusted between-group difference in systolic blood pressure was 6.1 mmHg in favor of the supplement. Pulse wave velocity, a measure of arterial stiffness, was also lower in the supplement group, with an adjusted difference of 1.18 m/s.
Blood tests showed no significant changes in cholesterol or other blood lipids, according to the report. Researchers said the estimated 10-year cardiovascular risk fell modestly, largely reflecting the difference in systolic blood pressure. That estimate is a risk calculation, not evidence that participants experienced fewer heart attacks or strokes.
What the Vascular Measures Show
The findings matter because the three measures capture different aspects of blood vessel health and are associated with cardiovascular risk. The reported blood-pressure difference is of a size that warrants further study: the researchers noted that previous large studies have linked a sustained 5 mmHg reduction in systolic pressure with an approximately 10% reduction in major cardiovascular events. That comparison comes from other research; it does not mean this trial demonstrated a similar reduction in events.
The results offer an early test of whether a supplement combining vitamins, minerals, amino acids and plant-derived bioactives can affect several aging-related processes at once. But the small trial measured biomarkers, not clinical outcomes. It cannot show whether the changes persist, apply to broader groups, or outweigh possible risks and costs. The evidence is preliminary, not a basis for treating or preventing cardiovascular disease.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Levoit Vital 100S-P Air Purifier for Home and Pets
Levoit Core 600S-P Smart Air Purifier for Large Rooms up to 2933 ft²
As an affiliate, we earn on qualifying purchases.
A Trial of Multiple Ingredients
The study, published in European Heart Journal Open, examined acute and six-month vascular effects of NOVOS Core. Its formulation was designed around ingredients selected for their relevance to multiple biological processes associated with aging. The researchers tested whether targeting several such processes simultaneously could produce measurable changes in cardiovascular biomarkers.
University of Surrey Professor Christian Heiss said the team focused first on established measures such as blood pressure and cholesterol rather than clinical outcomes. He called the changes in endothelial function, arterial stiffness and systolic pressure favorable, while saying larger studies are needed to investigate mechanisms and longer-term benefits. The study is reported by News-Medical and cited as Piercy and colleagues’ 2026 randomized trial.
“We now need larger studies to understand the mechanisms involved and, importantly, whether these changes translate into longer-term health benefits.”
— Christian Heiss, professor of cardiovascular medicine at the University of Surrey
Limits of the Current Evidence
The trial had 61 participants and ran for six months. The available report does not provide enough detail here to assess how well the sample represents the wider population, whether results differed among participant groups, or how the findings compare across different doses. It also does not establish the supplement’s long-term safety or whether the measured changes continue after people stop taking it.
Most importantly, researchers did not measure heart attacks, strokes, deaths or other clinical outcomes. The reported markers are associated with cardiovascular risk, but changes in them cannot by themselves prove that a product prevents disease. The report also does not establish which ingredients, if any, drove the observed differences.
Larger Studies Needed
The researchers have called for larger studies to test the results, explore the biological mechanisms and determine whether biomarker changes lead to lasting health benefits. Follow-up research would need to clarify the effects in broader populations and assess clinical outcomes over a longer period.
Until such evidence is available, the trial supports a limited conclusion: participants assigned to NOVOS Core had more favorable results on several vascular measures than those assigned to placebo during this study. Whether that translates into reduced cardiovascular disease remains unknown.
Key Questions
What did the trial find?
Compared with the placebo group, participants taking NOVOS Core had improved endothelial function, lower arterial stiffness and a lower systolic blood pressure measure after six months. The study also reported a blood-vessel-function change within an hour of the first dose.
How many people took part?
The trial included 61 participants: 33 received the supplement and 28 received a placebo. Both were taken once daily for six months.
Did the study show that the supplement prevents heart attacks or strokes?
No. The researchers measured vascular biomarkers and estimated risk; they did not test whether the supplement reduced heart attacks, strokes or deaths.
Did cholesterol levels change?
The report said blood tests showed no significant changes in cholesterol or other blood lipids. Researchers said the vascular-marker changes were not explained by lipid lowering.
What research is still needed?
Larger and longer studies are needed to examine how the supplement may affect vascular measures, whether changes persist and whether they lead to meaningful clinical benefits. The current trial does not establish long-term safety or effectiveness.
Source: news-medical.net
